Estimating Glomerular Filtration Rate in Patients With HIV Infection

Seminars in Nephrology

Volumn 28, Issue 6, 2008, Pages 576-580

  Winston, Jonathan A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cystatin C; estimated GFR; HIV infection; MDRD equation

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; CYSTATIN C;

ARTICLE; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; MALNUTRITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WASTING SYNDROME;

AIDS-ASSOCIATED NEPHROPATHY; CREATININE; CYSTATIN C; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 55649096158     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2008.08.001     Document Type: Article

References (21)

1. Choi A.I., Rodriguez R.A., Bacchetti P., Bertenthal D., Volberding P.A., and O'Hare A.M. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18 (2007) 2968-2974
2. Ross M.J., and Klotman P.E. HIV-associated nephropathy. AIDS 18 (2004) 1089-1099
3. Szczech L.A. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 33 (2001) 115-119
4. Wyatt C.M., Winston J.A., Malvestutto C.D., et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21 (2007) 2101-2103
5. Gupta S.K., Eustace J.A., Winston J.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2007), Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [accessed December 3, 2007]
7. Berns J.S., and Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 1 (2006) 117-129
8. Crane H.M., Kestenbaum B., Harrington R.D., and Kitahata M.M. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 21 (2007) 1431-1439
9. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
10. Goicoechea M., Liu S., Best B., et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197 (2008) 102-108
11. Stevens L.A., Coresh J., Feldman H.I., et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18 (2007) 2749-2757
12. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
13. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
14. Huang E., Hewitt R.G., Shelton M., and Morse G.D. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 16 (1996) 222-229
15. Smith B.L., Sarnoski T.P., Dennis S., and Luke D.R. Failure of predicted creatinine clearance equations in HIV-seropositive patients. Int J Clin Pharmacol Ther Toxicol 30 (1992) 394-399
16. Shlipak M.G. Cystatin C: research priorities targeted to clinical decision making. Am J Kidney Dis 51 (2008) 358-361
17. Stevens L.A., Coresh J., Schmid C.H., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51 (2008) 395-406
18. Odden M.C., Scherzer R., Bacchetti P., et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 167 (2007) 2213-2219
19. Jaroszewicz J., Wiercinska-Drapalo A., Lapinski T.W., Prokopowicz D., Rogalska M., and Parfieniuk A. Does HAART improve renal function?. An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther 11 (2006) 641-645
20. Kottgen A., Selvin E., Stevens L.A., Levey A.S., Van Lente F., and Coresh J. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51 (2008) 385-394
21. Szczech L.A., Grunfeld C., Scherzer R., et al. Microalbuminuria in HIV infection. AIDS 21 (2007) 1003-1009